The price-to-earnings ratio for Merck & Co Inc (NYSE: MRK) is above average at 57.03x. The 36-month beta value for MRK is also noteworthy at 0.36. There are mixed opinions on the stock, with 18 analysts rating it as a “buy,” 3 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”

The average price estimated by analysts for MRK is $124.74, which is $22.06 above than the current price. The public float for MRK is 2.53B, and at present, short sellers hold a 0.65% of that float. The average trading volume of MRK on November 21, 2023 was 6.66M shares.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"


MRK) stock’s latest price update

The stock price of Merck & Co Inc (NYSE: MRK) has surged by 0.91 when compared to previous closing price of 101.75, but the company has seen a 0.20% gain in its stock price over the last five trading sessions. Reuters reported 2023-11-17 that The U.S. health regulator’s advisers on Friday did not recommend Merck’s drug for the treatment of chronic cough.

MRK’s Market Performance

Merck & Co Inc (MRK) has seen a 0.20% rise in stock performance for the week, with a 0.01% gain in the past month and a -4.24% plunge in the past quarter. The volatility ratio for the week is 1.44%, and the volatility levels for the past 30 days are at 1.80% for MRK. The simple moving average for the past 20 days is -0.27% for MRK’s stock, with a -5.45% simple moving average for the past 200 days.

Analysts’ Opinion of MRK

Many brokerage firms have already submitted their reports for MRK stocks, with Deutsche Bank repeating the rating for MRK by listing it as a “Buy.” The predicted price for MRK in the upcoming period, according to Deutsche Bank is $115 based on the research report published on November 09, 2023 of the current year 2023.

MRK Trading at -1.36% from the 50-Day Moving Average

After a stumble in the market that brought MRK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.18% of loss for the given period.

Volatility was left at 1.80%, however, over the last 30 days, the volatility rate increased by 1.44%, as shares sank -0.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.45% lower at present.

During the last 5 trading sessions, MRK rose by +0.20%, which changed the moving average for the period of 200-days by -0.25% in comparison to the 20-day moving average, which settled at $102.92. In addition, Merck & Co Inc saw -7.45% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at MRK starting from Oosthuizen Johannes Jacobus, who sale 2,081 shares at the price of $102.38 back on Nov 09. After this action, Oosthuizen Johannes Jacobus now owns 18,191 shares of Merck & Co Inc, valued at $213,061 using the latest closing price.

DeLuca Richard R., the EVP&Pres, Merck Animal Heallth of Merck & Co Inc, sale 43,823 shares at $105.03 during a trade that took place back on Nov 08, which means that DeLuca Richard R. is holding 111,764 shares at $4,602,668 based on the most recent closing price.

Stock Fundamentals for MRK

Current profitability levels for the company are sitting at:

The net margin for Merck & Co Inc stands at +24.83. The total capital return value is set at 25.84, while invested capital returns managed to touch 19.91. Equity return is now at value 10.75, with 4.31 for asset returns.

Based on Merck & Co Inc (MRK), the company’s capital structure generated 69.55 points at debt to equity in total, while total debt to capital is 41.02. Total debt to assets is 29.30, with long-term debt to equity ratio resting at 64.70. Finally, the long-term debt to capital ratio is 38.16.

When we switch over and look at the enterprise to sales, we see a ratio of 4.76, with the company’s debt to enterprise value settled at 0.11. The receivables turnover for the company is 5.87 and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.47.


In summary, Merck & Co Inc (MRK) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.